Neoadjuvant PIK3CA Inhibition With Alpelisib in Head and Neck Squamous Cell Cancer: A Window-of-Opportunity Trial and Biomarker Study
PIK3CA -activating mutations and amplifications are common in both human papillomavirus (HPV)–positive and HPV-negative head and neck squamous cell carcinomas (HNSCCs). PI3K pathway inhibition is postulated as a potential therapeutic strategy, and preclinical studies have demonstrated that the PI3Kα selective in...